UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2020
XTANT MEDICAL HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-34951 | 20-5313323 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
664 Cruiser Lane Belgrade, Montana |
59714 | |
| (Address of principal executive offices) | (Zip Code) |
(406) 388-0480
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common stock, par value $0.000001 per share | XTNT | NYSE American LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
| Item 2.02 | Results of Operations and Financial Condition. |
On August 3, 2020, Xtant Medical Holdings, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2020. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
To supplement its consolidated financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures, such as non-GAAP adjusted EBITDA, which are included in the press release furnished as Exhibit 99.1 to this report. The Company’s non-GAAP adjusted EBITDA is calculated by adding back to net loss the charges for other expense, depreciation and amortization expense, interest expense, and tax expense and further adjusted by adding back in or excluding, as appropriate, provision for losses on accounts receivable, provision for excess and obsolete inventory, non-cash compensation, change in warrant derivative liability, separation-related expenses, field action expenses, and litigation reserve.
The Company uses adjusted EBITDA and the other non-GAAP measures in making operating decisions because it believes these measures provide meaningful supplemental information regarding its core operational performance. Additionally, these measures give the Company a better understanding of how it should invest in sales and marketing and research and development activities and how it should allocate resources to both ongoing and prospective business initiatives. The Company also uses these measures to help make budgeting and spending decisions, for example, among sales and marketing expenses, general and administrative expenses, and research and development expenses. Additionally, the Company believes its use of non-GAAP adjusted EBITDA and other non-GAAP measures facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges.
As described above, the Company excludes the following items from its non-GAAP financial measures for the following reasons:
Non-cash provision for losses on accounts receivable. The Company excludes non-cash provision for losses on accounts receivable primarily because such item is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Non-cash provision for excess and obsolete inventory. The Company excludes non-cash provision for excess and obsolete inventory primarily because such item is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Non-cash compensation. The Company excludes non-cash compensation, which is a non-cash charge related to equity awards granted by the Company. Although non-cash compensation is a recurring charge to the Company’s operations, management has excluded it because it relies on valuations based on future events, such as the market price of the Company’s common stock, that are difficult to predict and are affected by market factors that are largely not within the control of the Company. Thus, management believes that excluding non-cash compensation facilitates comparisons of the Company’s operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.
Change in warrant derivative liability. The Company excludes the change in fair market value of its warrants that are accounted for as liabilities from non-GAAP adjusted EBITDA primarily because it is a non-cash charge, it is not reflective of the Company’s ongoing operating results, and it is not used by management to assess the core profitability of the Company’s business operations. Because it is a non-cash expense, it does not impact the Company’s operational performance, liquidity, or ability to invest in sales and marketing, research and development, and fund acquisitions and capital expenditures. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Separation-related expenses. The Company excludes separation-related expenses from non-GAAP adjusted EBITDA primarily because such expenses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Field action expenses. The Company excludes expenses incurred in connection with the December 2018 recall of the Company’s Calix Lumbar Spine Implant System because such expenses are not reflective of its ongoing operating results and are not used by management to assess the core profitability of its business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Litigation reserve. The Company excludes litigation reserve from non-GAAP adjusted EBITDA primarily because it is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.
Non-GAAP adjusted EBITDA is reconciled to net loss, the most directly comparable GAAP measure, in the press release.
Non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, non-GAAP financial measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of the Company’s non-GAAP financial measures may differ from the definitions of other companies using the same or similar names, limiting, to some extent, the usefulness of such measures for comparison purposes. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company’s financial results as determined in accordance with GAAP. Non-GAAP financial measures should only be used to evaluate the Company’s financial results in conjunction with the corresponding GAAP measures. Accordingly, the Company qualifies its use of non-GAAP financial information in a statement when non-GAAP financial information is presented.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
Description | |
| 99.1 | Press Release of Xtant Medical Holdings, Inc. dated August 3, 2020 entitled “Xtant Medical Announces Second Quarter 2020 Financial Results” (furnished herewith) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| XTANT MEDICAL HOLDINGS, INC. | ||
| By: | /s/ Greg Jensen | |
| Greg Jensen | ||
| Vice President, Finance and Chief Financial Officer | ||
Date: August 3, 2020
Exhibit 99.1
Xtant Medical Announces Second Quarter 2020 Financial Results
BELGRADE, MT, August 3, 2020 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2020.
Second Quarter 2020 Financial Highlights:
| ● | Revenue for the second quarter of 2020 was $10.5 million, compared to $15.3 million for the prior-year period |
| ● | Operating expenses in the second quarter of 2020 were $6.9 million, compared to $10.5 million for the prior-year period |
| ● | Net loss incurred in the second quarter of 2020 was $2.5 million, compared to a net loss of $1.9 million for the prior-year period |
| ● | Adjusted EBITDA for the second quarter of 2020 was $0.7 million, compared to $1.1 million for the prior-year period |
“We are pleased with our second-quarter revenue performance primarily reflecting a rebound in spinal elective procedure volumes in June following sharp declines at the start of the COVID-19 pandemic,” said Sean Browne, President and CEO. “Our early actions to reduce expenses enabled us to conserve cash and rightsize our cost structure during this uncertain environment. Going forward, we believe operating as a leaner organization and improving our overall efficiencies will allow us to live our mission of ‘honoring the gift of donation, so our patients can live as full a life as possible.’”
COVID-19 Response Update
As previously announced, Xtant Medical identified four areas to maintain business continuity and emerge from the COVID-19 pandemic in a position of strength. We are committed to 1) Keeping our employees safe and healthy, (2) Conserving Cash, (3) Optimizing our production and thereby improving our inventory position, and (4) Improve our overall operational efficiency.
Second Quarter 2020 Financial Results
Total revenue for the three months ended June 30, 2020 was $10.5 million, which represents a decrease of 31.1% compared to $15.3 million in the same quarter of the prior year. The decrease in revenue is attributed primarily to the impact of COVID-19 and the sudden drop in elective procedures beginning in early March as result of the pandemic. Management anticipates that the current pandemic will impact revenue for the remainder of 2020.
Gross margin for the second quarter of 2020 was 62.2%, compared to 64.9% for the same period in 2019.
Operating expenses for the second quarter of 2020 were $6.9 million, compared to $10.5 million for the second quarter of 2019. The decrease was primarily due to a reduction in sales commissions, reduced salaries and wages, lower legal and consulting fees, reduced executive recruiting fees, and reduced legal settlement expenses, partially offset by additional stock-based compensation expense during the current year period.
Second quarter 2020 net loss was $2.5 million, or $0.19 per share, compared to second quarter 2019 net loss of $1.9 million, or $0.15 per share.
Adjusted EBITDA for the second quarter of 2020 was $0.7 million compared to $1.1 million for the same period in 2019. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash special charges, provision for losses on inventory and accounts receivable, non-cash compensation, change in warrant derivative liability, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.
Conference Call
Xtant Medical will host a webcast and conference call to discuss the second quarter 2020 financial results on Monday, August 3, 2020 at 4:30 PM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under “Investor Info.”
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Non-GAAP Financial Measures
To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Cautionary Statement Regarding Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company’s expectations that by operating as a leaner organization and improving its overall efficiencies it will be well-positioned to manage near-term challenges and that the current pandemic will impact revenue for the remainder of 2020. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: risks and uncertainities surrounding the debt restructuring transactions, including without limitation, the Company’s ability to consummate the restructuring transactions and to do so on a timely basis and its ability to maintain the listing of its common stock on the NYSE American; effect of the COVID-19 pandemic on the Company’s business, operating results and financial condition; the Company’s future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission (SEC) on March 5, 2020 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
Investor Relations Contact
David Carey
Lazar FINN
Ph: 212-867-1762
Email: dcarey@finnpartners.com
XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except number of shares and par value)
As of June 30, 2020 | As of December 31, 2019 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 3,019 | $ | 5,237 | ||||
| Trade accounts receivable, net of allowance for credit losses of $728 and doubtful accounts of $500, respectively | 7,583 | 10,124 | ||||||
| Inventories | 19,888 | 16,101 | ||||||
| Prepaid and other current assets | 899 | 784 | ||||||
| Total current assets | 31,389 | 32,246 | ||||||
| Property and equipment, net | 4,256 | 4,695 | ||||||
| Right-of -use asset, net | 1,898 | 2,100 | ||||||
| Goodwill | 3,205 | 3,205 | ||||||
| Intangible assets, net | 486 | 515 | ||||||
| Other assets | 432 | 394 | ||||||
| Total Assets | $ | 41,666 | $ | 43,155 | ||||
| LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 3,072 | $ | 2,188 | ||||
| Accrued liabilities | 5,894 | 6,632 | ||||||
| Current portion of lease liability | 408 | 394 | ||||||
| Current portion of financing lease obligations | 101 | 176 | ||||||
| Total current liabilities | 9,475 | 9,390 | ||||||
| Long-term Liabilities: | ||||||||
| Lease liability, less current portion | 1,518 | 1,726 | ||||||
| Long-term debt, plus premium and less issuance costs | 77,531 | 76,244 | ||||||
| Total Liabilities | 88,524 | 87,360 | ||||||
| Stockholders’ Equity (Deficit) | ||||||||
| Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding | - | - | ||||||
| Common stock, $0.000001 par value; 75,000,000 shares authorized; 13,223,565 shares issued and outstanding as of June 30, 2020 and 13,161,762 shares issued and outstanding as of December 31, 2019 | - | - | ||||||
| Additional paid-in capital | 181,412 | 179,061 | ||||||
| Accumulated deficit | (228,270 | ) | (223,266 | ) | ||||
| Total Stockholders’ Equity (Deficit) | (46,858 | ) | (44,205 | ) | ||||
| Total Liabilities & Stockholders’ Equity (Deficit) | $ | 41,666 | $ | 43,155 | ||||
XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in thousands, except number of shares and per share amounts)
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Revenue | ||||||||||||||||
| Orthopedic product sales | $ | 10,493 | $ | 15,197 | $ | 25,227 | $ | 31,883 | ||||||||
| Other revenue | 36 | 74 | 80 | 114 | ||||||||||||
| Total revenue | 10,529 | 15,271 | 25,307 | 31,997 | ||||||||||||
| Cost of sales | 3,979 | 5,365 | 9,144 | 11,278 | ||||||||||||
| Gross profit | 6,550 | 9,906 | 16,163 | 20,719 | ||||||||||||
| Gross profit % | 62.2 | % | 64.9 | % | 63.9 | % | 64.8 | % | ||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 2,931 | 4,187 | 7,250 | 8,664 | ||||||||||||
| Sales and marketing | 3,895 | 6,072 | 10,309 | 12,814 | ||||||||||||
| Research and development | 111 | 210 | 353 | 472 | ||||||||||||
| Total operating expenses | 6,937 | 10,469 | 17,912 | 21,950 | ||||||||||||
| Loss from operations | (387 | ) | (563 | ) | (1,749 | ) | (1,231 | ) | ||||||||
| Other (expense) income | ||||||||||||||||
| Interest expense | (2,054 | ) | (1,301 | ) | (3,163 | ) | (3,319 | ) | ||||||||
| Other (expense) income | - | (53 | ) | - | (143 | ) | ||||||||||
| Total Other (Expense) | (2,054 | ) | (1,354 | ) | (3,163 | ) | (3,462 | ) | ||||||||
| Net Loss Before Provision for Income Taxes | (2,441 | ) | (1,917 | ) | (4,912 | ) | (4,693 | ) | ||||||||
| Provision for income taxes | ||||||||||||||||
| Current and deferred | (23 | ) | (22 | ) | (45 | ) | (45 | ) | ||||||||
| Net Loss | $ | (2,464 | ) | $ | (1,939 | ) | $ | (4,957 | ) | $ | (4,738 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic | $ | (0.19 | ) | $ | (0.15 | ) | $ | (0.38 | ) | $ | (0.36 | ) | ||||
| Dilutive | $ | (0.19 | ) | $ | (0.15 | ) | $ | (0.38 | ) | $ | (0.36 | ) | ||||
| Shares used in the computation: | ||||||||||||||||
| Basic | 13,223,565 | 13,161,762 | 13,199,455 | 13,166,136 | ||||||||||||
| Dilutive | 13,223,565 | 13,161,762 | 13,199,455 | 13,166,136 | ||||||||||||
XTANT MEDICAL HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
| Six Months Ended June 30, | ||||||||
| 2020 | 2019 | |||||||
| Operating activities: | ||||||||
| Net loss | $ | (4,957 | ) | $ | (4,738 | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 1,153 | 1,559 | ||||||
| (Gain) loss on disposal of fixed assets | (118 | ) | 92 | |||||
| Non-cash interest | 3,149 | 3,272 | ||||||
| Non-cash rent expense | 8 | 11 | ||||||
| Stock-based compensation | 489 | 161 | ||||||
| Provision for reserve on accounts receivable | 204 | 232 | ||||||
| Provision for excess and obsolete inventory | 377 | 518 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 2,290 | 1,403 | ||||||
| Inventories | (4,164 | ) | 955 | |||||
| Prepaid and other assets | (153 | ) | 242 | |||||
| Accounts payable | 884 | (3,481 | ) | |||||
| Accrued liabilities | (738 | ) | 728 | |||||
| Net cash (used in) provided by operating activities | (1,576 | ) | 954 | |||||
| Investing activities: | ||||||||
| Purchases of property and equipment | (673 | ) | (211 | ) | ||||
| Proceeds from sale of fixed assets | 106 | 163 | ||||||
| Net cash used in investing activities | (567 | ) | (48 | ) | ||||
| Financing activities: | ||||||||
| Payments on financing leases | (75 | ) | (277 | ) | ||||
| Costs associated with Second Amended and Restated Credit Agreement | - | (108 | ) | |||||
| Net cash used in financing activities | (75 | ) | (385 | ) | ||||
| Net change in cash and cash equivalents | (2,218 | ) | 521 | |||||
| Cash and cash equivalents at beginning of period | 5,237 | 6,797 | ||||||
| Cash and cash equivalents at end of period | $ | 3,019 | $ | 7,318 | ||||
XTANT MEDICAL HOLDINGS, INC.
CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA
(Unaudited, in thousands)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
| Net Loss | $ | (2,464 | ) | $ | (1,939 | ) | $ | (4,957 | ) | $ | (4,738 | ) | ||||
| Other expense | 1 | 56 | 6 | 131 | ||||||||||||
| Depreciation and amortization | 468 | 783 | 1,153 | 1,559 | ||||||||||||
| Interest expense | 2,054 | 1,301 | 3,163 | 3,319 | ||||||||||||
| Tax expense | 23 | 22 | 45 | 45 | ||||||||||||
| Non-GAAP EBITDA | 82 | 223 | (590 | ) | 316 | |||||||||||
| Non-GAAP EBITDA/Total revenue | 0.8 | % | 1.5 | % | -2.3 | % | 1.0 | % | ||||||||
| NON-GAAP ADJUSTED EBITDA CALCULATION | ||||||||||||||||
| Provision for losses on accounts receivable | 66 | 138 | 204 | 232 | ||||||||||||
| Provision for excess and obsolete inventory | 346 | 365 | 377 | 518 | ||||||||||||
| Non-cash compensation | 219 | 39 | 489 | 161 | ||||||||||||
| Change in warrant derivative liability | (1 | ) | (3 | ) | (7 | ) | 12 | |||||||||
| Separation-related expenses | - | (15 | ) | 749 | (37 | ) | ||||||||||
| Field action expenses | - | 125 | - | 125 | ||||||||||||
| Litigation reserve | - | 270 | - | 800 | ||||||||||||
| Non-GAAP Adjusted EBITDA | $ | 712 | $ | 1,142 | $ | 1,222 | $ | 2,127 | ||||||||
| Non-GAAP Adjusted EBITDA/Total revenue | 6.8 | % | 7.5 | % | 4.8 | % | 6.6 | % | ||||||||